CV Sciences (CVSI) Income from Continuing Operations (2011 - 2026)
CV Sciences' (CVSI) quarterly Income from Continuing Operations came in at 643000.0 in Q1 2026, down 489.91% year-on-year from 164910.59 in Q1 2025, and down 269.66% quarter-over-quarter from 379000.0 in Q4 2025.
CV Sciences (CVSI) Income from Continuing Operations (2011 - 2026) Analysis & Trends
CV Sciences has disclosed Income from Continuing Operations across 16 years of filings, most recently posting 643000.0 for Q1 2026.
- Income from Continuing Operations for Q1 2026 came in at 643000.0, down 489.91% year-over-year; the trailing twelve-month figure through Mar 2026 was 907000.0 (up 51.63% YoY), and the FY2025 annual result was 373000.0, up 84.42% from the prior year.
- Income from Continuing Operations came in at 643000.0 for Q1 2026 at CV Sciences, down from 379000.0 in the prior quarter.
- In the past five years, Income from Continuing Operations ranged from a high of 5706000.0 in Q1 2023 to a low of 3983000.0 in Q4 2023.
- The 5-year median for Income from Continuing Operations is 628000.0 (2024), against an average of 643176.47.
- Across the five-year window, Income from Continuing Operations tumbled 2477.5% in 2022 and soared 476.63% in 2023, its largest moves.
- CV Sciences' Income from Continuing Operations stood at 2313000.0 in 2022, then plunged by 72.2% to 3983000.0 in 2023, then jumped by 81.77% to 726000.0 in 2024, then soared by 152.2% to 379000.0 in 2025, then slumped by 269.66% to 643000.0 in 2026.
- The last three Income from Continuing Operations figures came in at 643000.0 (Q1 2026), 379000.0 (Q4 2025), and 382000.0 (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Teva Pharmaceutical Industries | 38.34 Bn | 34.60 Bn | 1.97 Bn | 370.00 Mn |
| 2 | Zoetis | 33.27 Bn | 31.33 Bn | 1.62 Bn | 601.00 Mn |
| 3 | United Therapeutics | 23.75 Bn | 21.60 Bn | 648.10 Mn | 274.90 Mn |
| 4 | Aurora Cannabis | 17.11 Bn | 17.03 Bn | 33.43 Mn | 21.05 Mn |
| 5 | Neurocrine Biosciences | 16.37 Bn | 15.05 Bn | 800.70 Mn | 197.90 Mn |
| 6 | Elanco Animal Health | 11.78 Bn | 11.35 Bn | 785.00 Mn | 57.00 Mn |
| 7 | Alkermes | 7.05 Bn | 6.54 Bn | -116.06 Mn | -66.53 Mn |
| 8 | Lantheus Holdings | 6.49 Bn | 5.99 Bn | 230.92 Mn | 118.42 Mn |
| 9 | Hims & Hers Health | 6.19 Bn | 5.44 Bn | 396.79 Mn | -92.12 Mn |
| 10 | CV Sciences | - | - | 1.56 Mn | -643,000.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -643,000.00 |
| Dec 31, 2025 | 379,000.00 |
| Sep 30, 2025 | -382,000.00 |
| Jun 30, 2025 | -261,000.00 |
| Mar 31, 2025 | -109,000.00 |
| Dec 31, 2024 | -726,000.00 |
| Sep 30, 2024 | -456,000.00 |
| Jun 30, 2024 | -584,000.00 |
| Mar 31, 2024 | -628,000.00 |
| Dec 31, 2023 | -3.98 Mn |
| Sep 30, 2023 | -447,000.00 |
| Jun 30, 2023 | -1.29 Mn |
| Mar 31, 2023 | 5.71 Mn |
| Dec 31, 2022 | -2.31 Mn |
| Sep 30, 2022 | -1.03 Mn |
| Jun 30, 2022 | -2.65 Mn |
| Mar 31, 2022 | -1.52 Mn |
| Dec 31, 2021 | -8.86 Mn |
| Sep 30, 2021 | -40,000.00 |
| Jun 30, 2021 | -3.53 Mn |